Search

Your search keyword '"Osanto, Susanne"' showing total 291 results
Start Over Author "Osanto, Susanne"
291 results on '"Osanto, Susanne"'

5. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Author

Park, Se Hoon, van der Heijden, Michiel S., Necchi, Andrea, Castellano, Daniel, Bamias, Aristotelis, Lee, Jae Lyun, De Giorgi, Ugo, Bögemann, Martin, Eigl, Bernhard J., Tsiatas, Marinos, Powles, Thomas, Novikov, Andrey, Skoneczna, Iwona, Mukherjee, Som D., Suarez, Cristina, Westgeest, Hans, Fradet, Yves, Flechon, Aude, Ou, Yen-Chuan, Park, Inkeun, Matveev, Vsevolod, Pérez-Valderrama, Begoña, Cheng, Susanna, Frank, Stephen, Gurney, Howard, Anido, Urbano, Hamzaj, Alketa, Retz, Margitta, Sridhar, Srikala, Scagliotti, Giorgio Vittorio, Voortman, Jens, Alekseev, Boris, Alyasova, Anna, Komyakov, Boris, Dumez, Herlinde, Pavic, Michel, Kimura, Go, Mizokami, Atsushi, Osanto, Susanne, Arranz, Jose Angel, Piersma, Djura, Shin, Sang Joon, Karyakin, Oleg, Delgado, Ignacio, Gonzalez, Jose Luis, Pang, See-Tong, Tran, Anna, Lipatov, Oleg, Su, Wen-Pin, Flaig, Thomas, Alva, Ajjai, Park Kyong, Hwa, Kopyltsov, Evgeny, Almagro, Elena, Domenech, Monserrat, Chang, Yen-Hwa, Sautois, Brieuc, Ravaux, Andre, Aravantinos, Gerasimos, Georgoulias, Vasileios, Mulder, Sasja, Kim, Yu Jung, Kater, Fabio, Chevreau, Christine, Tagawa, Scott, Zalewski, Pawel, Joly, Florence, Loriot, Yohann, Hatiboglu, Gencay, Gianni, Luca, Morelli, Franco, Tambaro, Rosa, Hashimoto, Yasuhiro, Nosov, Alexander, Font, Albert, Rodriguez-Vida, Alejo M., Jones, Robert, Vasudev, Naveen, Srinivas, Sandhya, Zhang, Jingsong, Gil, Thierry, Finch, Daygen, Grimm, Marc-Oliver, Su, Yu-Li, Chowdhury, Simon, Hocking, Christopher, Plas, Eugen, North, Scott, Jensen, Niels Viggo, Theodore, Christine, Imkamp, Florian, Peer, Avivit, Kobayashi, Takashi, Sakai, Hideki, Sassa, Naoto, Yoshimura, Kazuhiro, Aarts, Maureen, Ferreira Castro, Ana, Topuzov, Marlen, Rodriguez, Juan Francisco, Vazquez, Federico Jose, Tsai, Yu-Chieh, Crabb, Simon, Hussain, Syed, Bendell, Johanna, Gross-Goupil, Marine, Gwenaelle, Gravis, Berger, Raanan, Statsenko, Galina, Evans, Linda, Drakaki, Alexandra, Somer, Bradley, Davis, Ian, Lynam, James, Borges, Giuliano, Dettino, Aldo, Fay, André P., Martins, Graziella, Zucca, Luis Eduardo, Agerbaek, Mads, Kalofonos, Haralambos, Rosenbaum, Eli, Enokida, Hideki, Kikukawa, Hiroaki, Nishimura, Kazuo, Tamada, Satoshi, Uemura, Motohide, Lopez, Yamil, Gietema, Jourik, Slojewski, Marcin, Fernandes, Isabel, Smolin, Alexey, Mazhar, Danish, Kalebasty, Arash Rezazadeh, Carthon, Bradley, Loidl, Wolfgang, Franke, Fabio, Girotto, Gustavo, Alimohamed, Nimira, Macfarlane, Robyn, Pappot, Helle, Niegisch, Guenter, Mavroudis, Dimitrios, Sella, Avishay, Porta, Camillo, Ebara, Shin, Nakamura, Motonobu, Obara, Wataru, Okuno, Norihiko, Shinohara, Nobuo, Sugimoto, Mikio, Suzuki, Akitaka, Tokuda, Noriaki, Uemura, Hiroji, Yamaguchi, Akito, Ramirez, Francisco, Rozanowski, Pawel, Wiechno, Pawel, Keam, Bhumsuk, Kislov, Nikolay, Plaksin, Denis, Cicin, Irfan, Kumar, Satish, Galsky, Matthew D., Petrylak, Daniel P., Rosales, Joseph, Vaishampayan, Ulka, Culine, Stephane, Papandreou, Christos, Nara, Taketoshi, Erman, Mustafa, Kreiger, Laurence, Janoski, Juliana, Rosa, Diogo, Siqueira, Mariana, Canil, Christina, Sengelov, Lisa, Tourani, Jean-Marc, Arai, Gaku, Hashine, Katsuyoshi, Kawakita, Mutsushi, Nakaigawa, Noboru, Nomi, Hayahito, Shiina, Hiroaki, Suzuki, Hiroyoshi, Yonese, Junji, Kuri, Roberto, Macedo, Eleazar, Rivera, Samuel, Villalobos Prieto, Alberto, Polakiewicz-Gilowska, Anna, Zaucha, Renata, Lopes, Fabio, Ponomarev, Roman, Pomerantz, Mark, Shariat, Shahrokh, Luk, Cynthia, Lesniewski-Kmak, Krzysztof, van der Heijden, Michiel S, Galsky, Matthew D, Petrylak, Daniel P, Ogawa, Osamu, Lee, Jae-Lyun, Eigl, Bernhard J, Mukherjee, Som D, Suárez, Cristina, Fay, André P, Duran, Ignacio, Wildsmith, Sophie, He, Philip, Angra, Natasha, Gupta, Ashok K, Levin, Wendy, and Bellmunt, Joaquim

Published
2020
Full Text
View/download PDF

7. Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting

Author

Aluwini, Shafak S., Mehra, Niven, Lolkema, Martijn P., Oprea-Lager, Daniela E., Yakar, Derya, Stoevelaar, Herman, van der Poel, Henk, Busstra, Martijn, de Jong, Igle-Jan, de Reijke, Theo, de Vries, Kim, Heijmink, Stijn, Jenster, Guido, Klaver, Sjoerd, Kneppers, Jeroen, Lavalaye, Jules, Leyten, Gisèle, Moonen, Luc, Nagaraj, James, Noordzij, Walter, Osanto, Susanne, Oving, Irma, Schaake, Eva, Scheenen, Tom, Schoots, Ivo, Sedelaar, Michiel, Somford, Diederik, van den Berkmortel, Franchette, van der Hulle, Tom, van der Voort van Zyp, Jochem, van Leeuwen, Pim, van Moorselaar, Jeroen, van Oort, Inge, Vogel, Wouter, and Westgeest, Hans

Published
2020
Full Text
View/download PDF

8. Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers

Author

Verhaart, Saskia Lisa, Abu-Ghanem, Yasmin, Mulder, Sasja F., Oosting, Sjoukje, Van Der Veldt, Astrid, Osanto, Susanne, Aarts, Maureen J.B., Houtsma, Danny, Peters, Frank P.J., Groenewegen, Gerard, Van Herpen, Carla M.L., Pronk, Loes M., Tascilar, Metin, Hamberg, Paul, Los, Maartje, Vreugdenhil, Gerard, Polee, Marco, Ten Tije, Albert J., Haanen, John B.A.G., Bex, Axel, and van den Eertwegh, Alfonsus J.

Published
2021
Full Text
View/download PDF

22. Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients

Author

Seyrek, Neslisah, primary, Hollemans, Eva, additional, Osanto, Susanne, additional, Pelger, Rob C M, additional, Poel, Henk G, additional, Bekers, Elise, additional, Bangma, Chris H, additional, Rietbergen, John, additional, Roobol, Monique J, additional, Schoots, Ivo G, additional, and Leenders, Geert J L H, additional

Published
2021
Full Text
View/download PDF

23. An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer

Author

Vrouwe, Josephina P. M., primary, Kamerling, Ingrid M. C., additional, Esdonk, Michiel J., additional, Metselaar, Josbert M., additional, Stuurman, Frederik E., additional, Pluijm, Gabri, additional, Burggraaf, Jacobus, additional, and Osanto, Susanne, additional

Published
2021
Full Text
View/download PDF

29. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multistakeholder effort† EU*ACME: under the auspices of the EAU-ESMO guidelines committees

Author

Witjes, J Alfred, Babjuk, Marek, Bellmunt, Joaquim, Bruins, H Maxim, De Reijke, Theo M, De Santis, Maria, Gillessen, Silke, James, Nicholas, Maclennan, Steven, Palou, Juan, Powles, Tom, Ribal, Maria J, Shariat, Shahrokh F, Der Kwast, Theo Van, Xylinas, Evanguelos, Agarwal, Neeraj, Arends, Tom, Bamias, Aristotle, Birtle, Alison, Black, Peter C, Bochner, Bernard H, Bolla, Michel, Boormans, Joost L, Bossi, Alberto, Briganti, Alberto, Brummelhuis, Iris, Burger, Max, Castellano, Daniel, Cathomas, Richard, Chiti, Arturo, Choudhury, Ananya, Compérat, Eva, Crabb, Simon, Culine, Stephane, De Bari, Berardino, De Blok, Willem, J L De Visschere, Pieter, Decaestecker, Karel, Dimitropoulos, Konstantinos, Dominguez-Escrig, Jose L, Fanti, Stefano, Fonteyne, Valerie, Frydenberg, Mark, Futterer, Jurgen J, Gakis, Georgios, Geavlete, Bogdan, Gontero, Paolo, Grubmüller, Bernhard, Hafeez, Shaista, Hansel, Donna E, Hartmann, Arndt, Hayne, Dickon, Henry, Ann M, Hernandez, Virginia, Herr, Harry, Herrmann, Ken, Hoskin, Peter, Huguet, Jorge, Jereczek-Fossa, Barbara A, Jones, Rob, Kamat, Ashish M, Khoo, Vincent, Kiltie, Anne E, Krege, Susanne, Ladoire, Sylvain, Lara, Pedro C, Leliveld, Annemarie, Linares-Espinós, Estefania, Løgager, Vibeke, Lorch, Anja, Loriot, Yohann, Meijer, Richard, Mir, M Carmen, Moschini, Marco, Mostafid, Hugh, Müller, Arndt-Christian, Müller, Christoph R, N'Dow, James, Necchi, Andrea, Neuzillet, Yann, Oddens, Jorg R, Oldenburg, Jan, Osanto, Susanne, J G Oyen, Wim, Pacheco-Figueiredo, Luís, Pappot, Helle, Patel, Manish I, Pieters, Bradley R, Plass, Karin, Remzi, Mesut, Retz, Margitta, Richenberg, Jonathan, Rink, Michael, Roghmann, Florian, Rosenberg, Jonathan E, Rouprêt, Morgan, Rouvière, Olivier, Salembier, Carl, Salminen, Antti, Sargos, Paul, Sengupta, Shomik, Sherif, Amir, Smeenk, Robert J, Smits, Anita, Stenzl, Arnulf, Thalmann, George N, Tombal, Bertrand, Turkbey, Baris, Lauridsen, Susanne Vahr, Valdagni, Riccardo, Der Heijden, Antoine G Van, Van Poppel, Hein, Vartolomei, Mihai D, Veskimäe, Erik, Vilaseca, Antoni, Rivera, Franklin A Vives, Wiegel, Thomas, Wiklund, Peter, Williams, Andrew, Zigeuner, Richard, and Horwich, Alan

Subjects
education
Abstract

Background: \ud Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial.\ud \ud Objective: \ud To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management.\ud \ud Design: \ud A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference.\ud \ud Setting: \ud Online Delphi survey and consensus conference.\ud \ud Participants: \ud The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management.\ud \ud Outcome measurements and statistical analysis: \ud Statements were ranked by experts according to their level of agreement: 1–3 (disagree), 4–6 (equivocal), and 7–9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus).\ud \ud Results and limitations: \ud Overall, 116 statements were included in the Delphi survey. Of these statements, 33 (28%) achieved level 1 consensus and 49 (42%) achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease, and the evolving role of checkpoint inhibitor therapy in metastatic disease.\ud \ud Conclusions: \ud These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time when further evidence is available to guide our approach.\ud \ud Patient summary: \ud This report summarises findings from an international, multistakeholder project organised by the EAU and ESMO. In this project, a steering committee identified areas of bladder cancer management where there is currently no good-quality evidence to guide treatment decisions. From this, they developed a series of proposed statements, 71 of which achieved consensus by a large group of experts in the field of bladder cancer. It is anticipated that these statements will provide further guidance to health care professionals and could help improve patient outcomes until a time when good-quality evidence is available.

Published
2020

30. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort †[Formula presented] : Under the Auspices of the EAU-ESMO Guidelines Committees

Author

Witjes, J. Alfred, Babjuk, Marek, Bellmunt, Joaquim, Bruins, H. Maxim, de Reijke, Theo M., de Santis, Maria, Gillessen, Silke, James, Nicholas, Maclennan, Steven, Palou, Juan, Powles, Tom, Ribal, Maria J., Shariat, Shahrokh F., der Kwast, Theo Van, Xylinas, Evanguelos, Agarwal, Neeraj, Arends, Tom, Bamias, Aristotle, Birtle, Alison, Black, Peter C., Bochner, Bernard H., Bolla, Michel, Boormans, Joost L., Bossi, Alberto, Briganti, Alberto, Brummelhuis, Iris, Burger, Max, Castellano, Daniel, Cathomas, Richard, Chiti, Arturo, Choudhury, Ananya, Compérat, Eva, Crabb, Simon, Culine, Stephane, de Bari, Berardino, de Blok, Willem, J.l. de Visschere, Pieter, Decaestecker, Karel, Dimitropoulos, Konstantinos, Dominguez-Escrig, Jose L., Fanti, Stefano, Fonteyne, Valerie, Frydenberg, Mark, Futterer, Jurgen J., Gakis, Georgios, Geavlete, Bogdan, Gontero, Paolo, Grubmüller, Bernhard, Hafeez, Shaista, Hansel, Donna E., Hartmann, Arndt, Hayne, Dickon, Henry, Ann M., Hernandez, Virginia, Herr, Harry, Herrmann, Ken, Hoskin, Peter, Huguet, Jorge, Jereczek-Fossa, Barbara A., Jones, Rob, Kamat, Ashish M., Khoo, Vincent, Kiltie, Anne E., Krege, Susanne, Ladoire, Sylvain, Lara, Pedro C., Leliveld, Annemarie, Linares-Espinós, Estefania, Løgager, Vibeke, Lorch, Anja, Loriot, Yohann, Meijer, Richard, Mir, M. Carmen, Moschini, Marco, Mostafid, Hugh, Müller, Arndt-Christian, Müller, Christoph R., N'Dow, James, Necchi, Andrea, Neuzillet, Yann, Oddens, Jorg R., Oldenburg, Jan, Osanto, Susanne, J.G. Oyen, Wim, Pacheco-Figueiredo, Luís, Pappot, Helle, Patel, Manish I., Pieters, Bradley R., Plass, Karin, Remzi, Mesut, Retz, Margitta, Richenberg, Jonathan, Rink, Michael, Roghmann, Florian, Rosenberg, Jonathan E., Rouprêt, Morgan, Rouvière, Olivier, Salembier, Carl, Salminen, Antti, Sargos, Paul, Sengupta, Shomik, Sherif, Amir, Smeenk, Robert J., Smits, Anita, Stenzl, Arnulf, Thalmann, George N., Tombal, Bertrand, Turkbey, Baris, Lauridsen, Susanne Vahr, Valdagni, Riccardo, der Heijden, Antoine G. Van, van Poppel, Hein, Vartolomei, Mihai D., Veskimäe, Erik, Vilaseca, Antoni, Rivera, Franklin A. Vives, Wiegel, Thomas, Wiklund, Peter, Williams, Andrew, Zigeuner, Richard, Horwich, Alan, Urology, APH - Personalized Medicine, APH - Quality of Care, CCA - Cancer Treatment and Quality of Life, and Radiotherapy

Subjects
Consensus, International Cooperation, Follow-up, Urology, education, Bladder cancer, Delphi, Treatment, Diagnosis, Humans, Neoplasm Staging, Urinary Bladder Neoplasms, Journal Article
Abstract

Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference. Setting: Online Delphi survey and consensus conference. Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1–3 (disagree), 4–6 (equivocal), and 7–9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Results and limitations: Overall, 116 statements were included in the Delphi survey. Of these statements, 33 (28%) achieved level 1 consensus and 49 (42%) achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease, and the evolving role of checkpoint inhibitor therapy in metastatic disease. Conclusions: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time when further evidence is available to guide our approach. Patient summary: This report summarises findings from an international, multistakeholder project organised by the EAU and ESMO. In this project, a steering committee identified areas of bladder cancer management where there is currently no good-quality evidence to guide treatment decisions. From this, they developed a series of proposed statements, 71 of which achieved consensus by a large group of experts in the field of bladder cancer. It is anticipated that these statements will provide further guidance to health care professionals and could help improve patient outcomes until a time when good-quality evidence is available.

Published
2020

31. AU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort : Under the Auspices of the EAU-ESMO Guidelines Committees

Author

Witjes, J. Alfred, Babjuk, Marek, Bellmunt, Joaquim, Maxim Bruins, H., De Reijke, Theo M., De Santis, Maria, Gillessen, Silke, James, Nicholas, Maclennan, Steven, Palou, Juan, Powles, Tom, Ribal, Maria J., Shariat, Shahrokh F., Van Der Kwast, Theo, Xylinas, Evanguelos, Agarwal, Neeraj, Arends, Tom, Bamias, Aristotle, Birtle, Alison, Black, Peter C., Bochner, Bernard H., Bolla, Michel, Boormans, Joost L., Bossi, Alberto, Briganti, Alberto, Brummelhuis, Iris, Burger, Max, Castellano, Daniel, Cathomas, Richard, Chiti, Arturo, Choudhury, Ananya, Compérat, Eva, Crabb, Simon, Culine, Stephane, De Bari, Berardino, De Blok, Willem, De Visschere, Pieter J.L., Decaestecker, Karel, Dimitropoulos, Konstantinos, Dominguez-Escrig, Jose L., Fanti, Stefano, Fonteyne, Valerie, Frydenberg, Mark, Futterer, Jurgen J., Gakis, Georgios, Geavlete, Bogdan, Gontero, Paolo, Grubmüller, Bernhard, Hafeez, Shaista, Hansel, Donna E., Hartmann, Arndt, Hayne, Dickon, Henry, Ann M., Hernandez, Virginia, Herr, Harry, Herrmann, Ken, Hoskin, Peter, Huguet, Jorge, Jereczek-Fossa, Barbara A., Jones, Rob, Kamat, Ashish M., Khoo, Vincent, Kiltie, Anne E., Krege, Susanne, Ladoire, Sylvain, Lara, Pedro C., Leliveld, Annemarie, Linares-Espinós, Estefania, Løgager, Vibeke, Lorch, Anja, Loriot, Yohann, Meijer, Richard, Carmen Mir, M., Moschini, Marco, Mostafid, Hugh, Müller, Arndt-Christian, Müller, Christoph R., N’dow, James, Necchi, Andrea, Neuzillet, Yann, Oddens, Jorg R., Oldenburg, Jan, Osanto, Susanne, Oyen, Wim J.G., Pacheco-Figueiredo, Luís, Pappot, Helle, Patel, Manish I., Pieters, Bradley R., Plass, Karin, Remzi, Mesut, Retz, Margitta, Richenberg, Jonathan, Rink, Michael, Roghmann, Florian, Rosenberg, Jonathan E., Rouprêt, Morgan, Rouvière, Olivier, Salembier, Carl, Salminen, Antti, Sargos, Paul, Sengupta, Shomik, Sherif, Amir, Smeenk, Robert J., Smits, Anita, Stenzl, Arnulf, Thalmann, George N., Tombal, Bertrand, Turkbey, Baris, Lauridsen, Susanne Vahr, Valdagni, Riccardo, Van Der Heijden, Antoine G., Van Poppel, Hein, Vartolomei, Mihai D., Veskimäe, Erik, Vilaseca, Antoni, Vives Rivera, Franklin A., Wiegel, Thomas, Wiklund, Peter, Williams, Andrew, Zigeuner, Richard, and Horwich, Alan

Subjects
Medizin
Published
2020

32. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees

Author

Witjes, J. Alfred, Babjuk, Marek, Bellmunt, Joaquim, Bruins, H. Maxim, De Reijke, Theo M., De Santis, Maria, Gillessen, Silke, James, Nicholas, Maclennan, Steven, Palou, Juan, Powles, Tom, Ribal, Maria J., Shariat, Shahrokh F., Van Der Kwast, Theo, Xylinas, Evanguelos, Agarwal, Neeraj, Arends, Tom, Bamias, Aristotle, Birtle, Alison, Black, Peter C., Bochner, Bernard H., Bolla, Michel, Boormans, Joost L., Bossi, Alberto, Briganti, Alberto, Brummelhuis, Iris, Burger, Max, Castellano, Daniel, Cathomas, Richard, Chiti, Arturo, Choudhury, Ananya, Compérat, Eva, Crabb, Simon, Culine, Stephane, De Bari, Berardino, De Blok, Willem, De Visschere, Pieter J.L., Decaestecker, Karel, Dimitropoulos, Konstantinos, Dominguez-Escrig, Jose L., Fanti, Stefano, Fonteyne, Valerie, Frydenberg, Mark, Futterer, Jurgen J., Gakis, Georgios, Geavlete, Bogdan, Gontero, Paolo, Grubmüller, Bernhard, Hafeez, Shaista, Hansel, Donna E., Hartmann, Arndt, Hayne, Dickon, Henry, Ann M., Hernandez, Virginia, Herr, Harry, Herrmann, Ken, Hoskin, Peter, Huguet, Jorge, Jereczek-Fossa, Barbara A., Jones, Rob, Kamat, Ashish M., Khoo, Vincent, Kiltie, Anne E., Krege, Susanne, Ladoire, Sylvain, Lara, Pedro C., Leliveld, Annemarie, Linares-Espinós, Estefania, Løgager, Vibeke, Lorch, Anja, Loriot, Yohann, Meijer, Richard, Mir, M. Carmen, Moschini, Marco, Mostafid, Hugh, Müller, Arndt-Christian, Müller, Christoph R., N'Dow, James, Necchi, Andrea, Neuzillet, Yann, Oddens, Jorg R., Oldenburg, Jan, Osanto, Susanne, Oyen, Wim J.G., Pacheco-Figueiredo, Luís, Pappot, Helle, Patel, Manish I., Pieters, Bradley R., Plass, Karin, Remzi, Mesut, Retz, Margitta, Richenberg, Jonathan, Rink, Michael, Roghmann, Florian, Rosenberg, Jonathan E., Rouprêt, Morgan, Rouvière, Olivier, Salembier, Carl, Salminen, Antti, Sargos, Paul, Sengupta, Shomik, Sherif, Amir, Smeenk, Robert J., Smits, Anita, Stenzl, Arnulf, Thalmann, George N., Tombal, Bertrand, Turkbey, Baris, Lauridsen, Susanne Vahr, Valdagni, Riccardo, Van Der Heijden, Antoine G., Van Poppel, Hein, Vartolomei, Mihai D., Veskimäe, Erik, Vilaseca, Antoni, Rivera, Franklin A. Vives, Wiegel, Thomas, Wiklund, Peter, Willemse, Peter-Paul M., Williams, Andrew, Zigeuner, Richard, and Horwich, Alan

Subjects
Medizin
Abstract

Korrektur zu 10.1016/j.eururo.2019.09.035

Published
2020

35. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Author

Powles, Thomas, primary, van der Heijden, Michiel S, additional, Castellano, Daniel, additional, Galsky, Matthew D, additional, Loriot, Yohann, additional, Petrylak, Daniel P, additional, Ogawa, Osamu, additional, Park, Se Hoon, additional, Lee, Jae-Lyun, additional, De Giorgi, Ugo, additional, Bögemann, Martin, additional, Bamias, Aristotelis, additional, Eigl, Bernhard J, additional, Gurney, Howard, additional, Mukherjee, Som D, additional, Fradet, Yves, additional, Skoneczna, Iwona, additional, Tsiatas, Marinos, additional, Novikov, Andrey, additional, Suárez, Cristina, additional, Fay, André P, additional, Duran, Ignacio, additional, Necchi, Andrea, additional, Wildsmith, Sophie, additional, He, Philip, additional, Angra, Natasha, additional, Gupta, Ashok K, additional, Levin, Wendy, additional, Bellmunt, Joaquim, additional, van der Heijden, Michiel S., additional, Lee, Jae Lyun, additional, Eigl, Bernhard J., additional, Powles, Thomas, additional, Mukherjee, Som D., additional, Suarez, Cristina, additional, Westgeest, Hans, additional, Flechon, Aude, additional, Ou, Yen-Chuan, additional, Park, Inkeun, additional, Matveev, Vsevolod, additional, Pérez-Valderrama, Begoña, additional, Cheng, Susanna, additional, Frank, Stephen, additional, Anido, Urbano, additional, Hamzaj, Alketa, additional, Retz, Margitta, additional, Sridhar, Srikala, additional, Scagliotti, Giorgio Vittorio, additional, Voortman, Jens, additional, Alekseev, Boris, additional, Alyasova, Anna, additional, Komyakov, Boris, additional, Dumez, Herlinde, additional, Pavic, Michel, additional, Kimura, Go, additional, Mizokami, Atsushi, additional, Osanto, Susanne, additional, Arranz, Jose Angel, additional, Piersma, Djura, additional, Shin, Sang Joon, additional, Karyakin, Oleg, additional, Delgado, Ignacio, additional, Gonzalez, Jose Luis, additional, Pang, See-Tong, additional, Tran, Anna, additional, Lipatov, Oleg, additional, Su, Wen-Pin, additional, Flaig, Thomas, additional, Alva, Ajjai, additional, Park Kyong, Hwa, additional, Kopyltsov, Evgeny, additional, Almagro, Elena, additional, Domenech, Monserrat, additional, Chang, Yen-Hwa, additional, Sautois, Brieuc, additional, Ravaux, Andre, additional, Aravantinos, Gerasimos, additional, Georgoulias, Vasileios, additional, Mulder, Sasja, additional, Kim, Yu Jung, additional, Kater, Fabio, additional, Chevreau, Christine, additional, Tagawa, Scott, additional, Zalewski, Pawel, additional, Joly, Florence, additional, Hatiboglu, Gencay, additional, Gianni, Luca, additional, Morelli, Franco, additional, Tambaro, Rosa, additional, Hashimoto, Yasuhiro, additional, Nosov, Alexander, additional, Font, Albert, additional, Rodriguez-Vida, Alejo M., additional, Jones, Robert, additional, Vasudev, Naveen, additional, Srinivas, Sandhya, additional, Zhang, Jingsong, additional, Gil, Thierry, additional, Finch, Daygen, additional, Grimm, Marc-Oliver, additional, Su, Yu-Li, additional, Chowdhury, Simon, additional, Hocking, Christopher, additional, Plas, Eugen, additional, North, Scott, additional, Jensen, Niels Viggo, additional, Theodore, Christine, additional, Imkamp, Florian, additional, Peer, Avivit, additional, Kobayashi, Takashi, additional, Sakai, Hideki, additional, Sassa, Naoto, additional, Yoshimura, Kazuhiro, additional, Aarts, Maureen, additional, Ferreira Castro, Ana, additional, Topuzov, Marlen, additional, Rodriguez, Juan Francisco, additional, Vazquez, Federico Jose, additional, Tsai, Yu-Chieh, additional, Crabb, Simon, additional, Hussain, Syed, additional, Bendell, Johanna, additional, Gross-Goupil, Marine, additional, Gwenaelle, Gravis, additional, Berger, Raanan, additional, Statsenko, Galina, additional, Evans, Linda, additional, Drakaki, Alexandra, additional, Somer, Bradley, additional, Davis, Ian, additional, Lynam, James, additional, Borges, Giuliano, additional, Dettino, Aldo, additional, Fay, André P., additional, Martins, Graziella, additional, Zucca, Luis Eduardo, additional, Agerbaek, Mads, additional, Kalofonos, Haralambos, additional, Rosenbaum, Eli, additional, Enokida, Hideki, additional, Kikukawa, Hiroaki, additional, Nishimura, Kazuo, additional, Tamada, Satoshi, additional, Uemura, Motohide, additional, Lopez, Yamil, additional, Gietema, Jourik, additional, Slojewski, Marcin, additional, Fernandes, Isabel, additional, Smolin, Alexey, additional, Mazhar, Danish, additional, Kalebasty, Arash Rezazadeh, additional, Carthon, Bradley, additional, Loidl, Wolfgang, additional, Franke, Fabio, additional, Girotto, Gustavo, additional, Alimohamed, Nimira, additional, Macfarlane, Robyn, additional, Pappot, Helle, additional, Niegisch, Guenter, additional, Mavroudis, Dimitrios, additional, Sella, Avishay, additional, Porta, Camillo, additional, Ebara, Shin, additional, Nakamura, Motonobu, additional, Obara, Wataru, additional, Okuno, Norihiko, additional, Shinohara, Nobuo, additional, Sugimoto, Mikio, additional, Suzuki, Akitaka, additional, Tokuda, Noriaki, additional, Uemura, Hiroji, additional, Yamaguchi, Akito, additional, Ramirez, Francisco, additional, Rozanowski, Pawel, additional, Wiechno, Pawel, additional, Keam, Bhumsuk, additional, Kislov, Nikolay, additional, Plaksin, Denis, additional, Cicin, Irfan, additional, Kumar, Satish, additional, Galsky, Matthew D., additional, Petrylak, Daniel P., additional, Rosales, Joseph, additional, Vaishampayan, Ulka, additional, Culine, Stephane, additional, Papandreou, Christos, additional, Nara, Taketoshi, additional, Erman, Mustafa, additional, Kreiger, Laurence, additional, Janoski, Juliana, additional, Rosa, Diogo, additional, Siqueira, Mariana, additional, Canil, Christina, additional, Sengelov, Lisa, additional, Tourani, Jean-Marc, additional, Arai, Gaku, additional, Hashine, Katsuyoshi, additional, Kawakita, Mutsushi, additional, Nakaigawa, Noboru, additional, Nomi, Hayahito, additional, Shiina, Hiroaki, additional, Suzuki, Hiroyoshi, additional, Yonese, Junji, additional, Kuri, Roberto, additional, Macedo, Eleazar, additional, Rivera, Samuel, additional, Villalobos Prieto, Alberto, additional, Polakiewicz-Gilowska, Anna, additional, Zaucha, Renata, additional, Lopes, Fabio, additional, Ponomarev, Roman, additional, Pomerantz, Mark, additional, Shariat, Shahrokh, additional, Luk, Cynthia, additional, and Lesniewski-Kmak, Krzysztof, additional

Published
2020
Full Text
View/download PDF

36. Malignancies, prothrombotic mutations, and the risk of venous thrombosis

Author

Blom, Jeanet W., Doggen, Carine J. M., Osanto, Susanne, and Rosendaal, Frits R.

Subjects
Cancer patients -- Health aspects, Thrombophlebitis -- Risk factors, Medical research, Medicine, Experimental
Abstract

The study aimed to identify individuals with cancer with an increased thrombotic risk, evaluating different tumor sites, the presence of distant metabases, and carrier status of prothrombotic mutations. It concluded that patients with cancer have a highly increased risk of venous thrombosis especially in the first few months after diagnosis and in the presence of distant metastases.

Published
2005

37. Reply

Author

Osanto, Susanne, Vossen, Carla, Horwich, Alan, Daugaard, Gedske, and Van Poppel, Hendrik

Published
2013
Full Text
View/download PDF

38. Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients.

Author

Seyrek, Neslisah, Hollemans, Eva, Osanto, Susanne, Pelger, Rob C M, van der Poel, Henk G, Bekers, Elise, Bangma, Chris H, Rietbergen, John, Roobol, Monique J, Schoots, Ivo G, and van Leenders, Geert J L H

Subjects
PROSTATE cancer patients, RADICAL prostatectomy, PERCENTILES
Abstract

Aims: Gleason pattern 4 (GP4) percentage, invasive cribriform and/or intraductal carcinoma (IC/IDC) and the presence of tertiary Gleason pattern 5 (TP5) in radical prostatectomy (RP) specimens all aid in the risk stratification of Grade Group (GG) 2 prostate cancer patients. However, it is unclear to what extent these pathological features are mutually related and what are their individual values if they are investigated simultaneously. The aims of this study were: (i) to determine the mutual relationships of the GP4 percentage, IC/IDC and TP5 in GG2 RP specimens; and (ii) to assess their prognostic value for biochemical recurrence‐free survival (BCRFS). Methods and results: Of 1064 RP specimens, 472 (44.4%) showed GG2 prostate cancer. Patients with ≥25% GP4 more frequently had IC/IDC (67.0% versus 43.9%; P < 0.001) and TP5 (20.6% versus 5.8%; P < 0.001) than those with <25% GP4. In unadjusted analysis, an increased GP4 percentage [hazard ratio (HR) 1.3; 95% confidence interval (CI) 1.0–1.6; P = 0.04] and IC/IDC (log rank P < 0.001) were associated with shorter BCRFS, whereas TP5 (P = 0.12) and a dichotomised (<25%, ≥25%) GP4 percentage (P = 0.10) were not. In multivariable analysis, IC/IDC was an independent prognostic factor (HR 1.9; 95% CI 1.2–2.9; P = 0.005) for BCRFS, whereas a continuous or dichotomised GP4 percentage and TP5 were not independent prognostic factors. Conclusion: In conclusion, a higher GP4 percentage in RP specimens was associated with more frequent IC/IDC and TP5. IC/IDC was an independent predictor for BCRFS, whereas the GP4 percentage and TP5 were not. These findings underscore the importance of routinely including the presence of IC/IDC in RP pathology reports. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

41. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250]

Author

Witjes, J. Alfred, primary, Babjuk, Marek, additional, Bellmunt, Joaquim, additional, Bruins, H. Maxim, additional, De Reijke, Theo M., additional, De Santis, Maria, additional, Gillessen, Silke, additional, James, Nicholas, additional, Maclennan, Steven, additional, Palou, Juan, additional, Powles, Tom, additional, Ribal, Maria J., additional, Shariat, Shahrokh F., additional, Van Der Kwast, Theo, additional, Xylinas, Evanguelos, additional, Agarwal, Neeraj, additional, Arends, Tom, additional, Bamias, Aristotle, additional, Birtle, Alison, additional, Black, Peter C., additional, Bochner, Bernard H., additional, Bolla, Michel, additional, Boormans, Joost L., additional, Bossi, Alberto, additional, Briganti, Alberto, additional, Brummelhuis, Iris, additional, Burger, Max, additional, Castellano, Daniel, additional, Cathomas, Richard, additional, Chiti, Arturo, additional, Choudhury, Ananya, additional, Compérat, Eva, additional, Crabb, Simon, additional, Culine, Stephane, additional, De Bari, Berardino, additional, De Blok, Willem, additional, De Visschere, Pieter J.L., additional, Decaestecker, Karel, additional, Dimitropoulos, Konstantinos, additional, Dominguez-Escrig, Jose L., additional, Fanti, Stefano, additional, Fonteyne, Valerie, additional, Frydenberg, Mark, additional, Futterer, Jurgen J., additional, Gakis, Georgios, additional, Geavlete, Bogdan, additional, Gontero, Paolo, additional, Grubmüller, Bernhard, additional, Hafeez, Shaista, additional, Hansel, Donna E., additional, Hartmann, Arndt, additional, Hayne, Dickon, additional, Henry, Ann M., additional, Hernandez, Virginia, additional, Herr, Harry, additional, Herrmann, Ken, additional, Hoskin, Peter, additional, Huguet, Jorge, additional, Jereczek-Fossa, Barbara A., additional, Jones, Rob, additional, Kamat, Ashish M., additional, Khoo, Vincent, additional, Kiltie, Anne E., additional, Krege, Susanne, additional, Ladoire, Sylvain, additional, Lara, Pedro C., additional, Leliveld, Annemarie, additional, Linares-Espinós, Estefania, additional, Løgager, Vibeke, additional, Lorch, Anja, additional, Loriot, Yohann, additional, Meijer, Richard, additional, Mir, M. Carmen, additional, Moschini, Marco, additional, Mostafid, Hugh, additional, Müller, Arndt-Christian, additional, Müller, Christoph R., additional, N’Dow, James, additional, Necchi, Andrea, additional, Neuzillet, Yann, additional, Oddens, Jorg R., additional, Oldenburg, Jan, additional, Osanto, Susanne, additional, Oyen, Wim J.G., additional, Pacheco-Figueiredo, Luís, additional, Pappot, Helle, additional, Patel, Manish I., additional, Pieters, Bradley R., additional, Plass, Karin, additional, Remzi, Mesut, additional, Retz, Margitta, additional, Richenberg, Jonathan, additional, Rink, Michael, additional, Roghmann, Florian, additional, Rosenberg, Jonathan E., additional, Rouprêt, Morgan, additional, Rouvière, Olivier, additional, Salembier, Carl, additional, Salminen, Antti, additional, Sargos, Paul, additional, Sengupta, Shomik, additional, Sherif, Amir, additional, Smeenk, Robert J., additional, Smits, Anita, additional, Stenzl, Arnulf, additional, Thalmann, George N., additional, Tombal, Bertrand, additional, Turkbey, Baris, additional, Lauridsen, Susanne Vahr, additional, Valdagni, Riccardo, additional, Van Der Heijden, Antoine G., additional, Van Poppel, Hein, additional, Vartolomei, Mihai D., additional, Veskimäe, Erik, additional, Vilaseca, Antoni, additional, Rivera, Franklin A. Vives, additional, Wiegel, Thomas, additional, Wiklund, Peter, additional, Willemse, Peter-Paul M., additional, Williams, Andrew, additional, Zigeuner, Richard, additional, and Horwich, Alan, additional

Published
2020
Full Text
View/download PDF

44. Tumoral and Immunologic Response After Vaccination of Melanoma Patients With an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells

Author

van Baren, Nicolas, Bonnet, Marie-Claude, Dréno, Brigitte, Khammari, Amir, Dorval, Thierry, Piperno-Neumann, Sophie, Liénard, Danielle, Speiser, Daniel, Marchand, Marie, Brichard, Vincent G, Escudier, Bernard, Négrier, Sylvie, Dietrich, Pierre-Yves, Maraninchi, Dominique, Osanto, Susanne, Meyer, Ralf G, Ritter, Gerd, Moingeon, Philippe, Tartaglia, Jim, van der Bruggen, Pierre, Coulie, Pierre G, and Boon, Thierry

Published
2005
Full Text
View/download PDF

49. Lifetime Transfusion Burden and Transfusion‐Related Iron Overload in Adult Survivors of Solid Malignancies.

Author

Woei‐A‐Jin, F.J. Sherida H., Zheng, Shu Zhen, Kiliçsoy, Inci, Hudig, Francisca, Luelmo, Saskia A.C., Kroep, Judith R., Lamb, Hildo J., and Osanto, Susanne

Subjects
ACADEMIC medical centers, ERYTHROCYTES, BLOOD transfusion, CANCER chemotherapy, CANCER patients, REPORTING of diseases, FERRITIN, HEMOGLOBINS, IRON in the body, MAGNETIC resonance imaging, MEDICAL records, NONPARAMETRIC statistics, STATISTICS, SURVIVAL, TUMORS, DATA analysis, DATA analysis software, DESCRIPTIVE statistics, ACQUISITION of data methodology, MANN Whitney U Test, KRUSKAL-Wallis Test
Abstract

Background: Limited data exist on transfusion burden and transfusion‐related iron overload in adult survivors of solid malignancies. Methods: Hospital‐specific cancer registry data of patients with solid tumor receiving systemic anticancer treatment between January 2008 and September 2009 at the Oncology Department of the Leiden University Medical Center (The Netherlands) were retrieved and cross‐referenced with red blood cell (RBC) transfusion records. Individual lifetime transfusion burden was captured in April 2015. Multitransfused long‐term survivors with serum ferritin >500 μg/L were subsequently screened for hepatic and cardiac iron overload using 1.5 Tesla magnetic resonance imaging. Results: The study population consisted of 775 adult patients with solid cancer (45.2% male; median age, 58 years; >75% chemotherapy‐treated), 423 (54.6%) of whom were transfused with a median of 6.0 RBC units (range 1–67). Transfusion triggers were symptomatic anemia or hemoglobin <8.1–8.9 g/dL prior to each myelosuppressive chemotherapy cycle. We identified 123 (15.9%) patients across all tumor types with a lifetime transfusion burden of ≥10 RBC units. In the absence of a hemovigilance program, none of these multitransfused patients was screened for iron overload despite a median survival of 4.6 years. In 2015 at disclosure of transfusion burden, 26 multitransfused patients were alive. Six (23.1%) had hepatic iron overload: 3.9–11.2 mg Fe/g dry weight. No cardiac iron depositions were found. Conclusion: Patients with solid malignancies are at risk for multitransfusion and iron overload even when adhering to restrictive RBC transfusion policies. With improved long‐term cancer survivorship, increased awareness of iatrogenic side effects of supportive therapy and development of evidence‐based guidelines are essential. Implications for Practice: In the presence of a restrictive transfusion policy, ∼30% of transfused adult patients with solid cancer are multitransfused and ∼50% become long‐term survivors, underscoring the need for evidence‐based guidelines for the detection and management of transfusion‐related iron overload in this group of patients. In each institution, a hemovigilance program should be implemented that captures the lifetime cumulative transfusion burden in all patients with cancer, irrespective of tumor type. This instrument will allow timely assessment and treatment of iron overload in cancer survivors, thus preventing organ dysfunction and decreased quality of life. This large real‐world study was conducted to gain more insight in the occurrence of transfusion‐related iron overload in patients with solid malignancies. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results